GICS Sector : Healthcare
AbbVie Inc.discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
AbbVie's third-quarter 2025 financial performance was impressive, with adjusted earnings per share (EPS) of $1.86, beating estimates of $1.77. Total net revenues reached nearly $15.8 billion, reflecting an 8.4% growth on an operational basis and surpassing expectations by approximately $300 million. The company's adjusted gross margin was 83.9% of sales, and the adjusted operating margin ratio was 30.9% of sales.
Publication Date: Nov -04
The growth was primarily driven by AbbVie's ex-Humira growth platform, which delivered reported sales growth of more than 20%. The immunology segment, led by Skyrizi and Rinvoq, achieved total revenues of approximately $7.9 billion, up 11.2% on an operational basis. Jeff Stewart, Executive Vice President and Chief Commercial Officer, noted that Skyrizi and Rinvoq continue to exceed expectations, demonstrating robust growth across a broad set of indications.
With a P/E Ratio of 99.65 and an EV/EBITDA of 30.96, AbbVie's valuation suggests that the market has high expectations for the company's future growth. The Dividend Yield of 3.09% indicates a relatively stable return for investors. The company's ROE of 142.31% and ROIC of 14.16% demonstrate its ability to generate strong returns on equity and invested capital.
AbbVie is making significant progress in its pipeline, with approximately 90 programs across all stages of development. The company expects several important milestones over the next two years, including new product approvals for tavapadon and PVEK, and expanded indications for Rinvoq, Epkinly, Qulipta, and Ubrelvy. Roopal Thakkar, Executive Vice President, Research and Development, and Chief Scientific Officer, highlighted the potential of Rinvoq in treating alopecia areata and vitiligo.
AbbVie raised its full-year adjusted EPS guidance to between $10.61 and $10.65 and now expects total net revenues of approximately $62.8 billion for the full year, an increase of $400 million. The company is confident in its ability to deliver strong growth next year, despite headwinds from continued Humira erosion and Imbruvica IRA pricing. Analysts estimate next year's revenue growth at 9.2%, indicating a continued upward trajectory for the company.
Could Buying AbbVie Today Set You Up for Life?
Dec -04
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
Dec -04
Groupe la Francaise Purchases 6,466 Shares of AbbVie Inc. $ABBV
Dec -04
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Dec -03
AbbVie Inc. (NYSE:ABBV) Receives Average Rating of “Moderate Buy” from Analysts
Dec -03
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Dec -02
À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraine
Dec -02
AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen
Dec -02
AbbVie's biopharmaceuticals' growth is driven by increasing demand for innovative therapies, strong R&D pipeline, and strategic collaborations, leading to a forecasted 10.3% growth rate.
Humira is a prescription medication used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Imbruvica is a prescription medication used to treat certain types of blood cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.
Venclexta is a prescription medication used to treat chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Mavyret is a prescription medication used to treat chronic hepatitis C virus (HCV) infection.
Rinvoq is a prescription medication used to treat moderate to severe rheumatoid arthritis.
Skyrizi is a prescription medication used to treat moderate to severe plaque psoriasis.
Ubrelvy is a prescription medication used to treat acute migraine attacks.
AbbVie Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for various diseases. However, the company's strong brand recognition and patented products mitigate this threat to some extent.
AbbVie Inc. has a low bargaining power of customers due to the lack of concentration in the buyer's market. The company's products are often prescribed by doctors, reducing the bargaining power of individual customers.
AbbVie Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services. However, the company's large scale of operations and long-term contracts with suppliers mitigate this threat to some extent.
AbbVie Inc. has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including significant R&D investments and regulatory hurdles.
AbbVie Inc. operates in a highly competitive pharmaceutical industry, with many established players and new entrants vying for market share. The company faces intense competition in various therapeutic areas, including immunology, oncology, and virology.
| Value | |
|---|---|
| Debt Weight | 85.15% |
| Debt Cost | 3.95% |
| Equity Weight | 14.85% |
| Equity Cost | 7.07% |
| WACC | 4.41% |
| Leverage | 573.21% |
Value: 3.0
Growth: 4.7
Quality: 7.5
Yield: 7.0
Momentum: 8.5
Volatility: 9.0
1-Year Total Return ->
Value: 3.3
Growth: 3.0
Quality: 8.6
Yield: 7.0
Momentum: 9.0
Volatility: 8.3
1-Year Total Return ->
Value: 3.0
Growth: 4.0
Quality: 7.7
Yield: 6.0
Momentum: 8.0
Volatility: 10.0
1-Year Total Return ->
Value: 4.8
Growth: 6.2
Quality: 7.8
Yield: 7.0
Momentum: 1.5
Volatility: 8.3
1-Year Total Return ->
Value: 5.0
Growth: 3.9
Quality: 6.4
Yield: 8.0
Momentum: 2.0
Volatility: 8.3
1-Year Total Return ->
Value: 2.9
Growth: 5.2
Quality: 6.8
Yield: 6.0
Momentum: 3.0
Volatility: 8.3
1-Year Total Return ->